| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Pathology and Kaplan Comprehensive CancerCenter,* New York University School of Medicine, New York,New York; the Department of Pathology,University of Torino, Torino, Italy; the Department of Pathology andExperimental Medicine Research Center,University of Verona, Verona, Italy; and the Division of Morphology andMolecular Pathology, Catholic UniversityLeuven, Leuven, Belgium
The protein expression of the cyclin-dependent kinase inhibitor p27 is often deregulated in human tumors. In lymphomas the inactivation of p27 is achieved through either increased degradation1 or sequestration via D cyclins,2 and p27 protein levels have been shown to have a prognostic significance.1,3 Recently, S-phase kinase-associated protein 2 (Skp2) has been proved to mediate p27 degradation in normal cells4-7 and to have oncogenetic properties.8,9 In this study, B-, T-, and myeloid hematopoietic cell lines and a well-characterized panel of human lymphomas (n = 244) were studied for the expression of Skp2. In human lymphomas, the expression of Skp2 strongly related to the grade of malignancy, being low in indolent tumors and very high in aggressive lymphomas. Moreover, the percentages of Skp2- and S-phase-positive cells, as measured by DNA content or BrdU labeling, strictly matched and closely parallel that of Ki-67 and cyclin A. An inverse correlation between Skp2 and p27 was found in the majority of lymphoma subtypes. Nonetheless, most mantle cell lymphomas and a subset of diffuse large cell lymphomas failed to show this correlation, suggesting that alternative pathway(s) for the regulation of p27 might exist. The detection of Skp2 protein either by flow cytometry or by immunohistochemistry represents a simple method to precisely assess the S phase of lymphomas. The potential diagnostic and prognostic value of Skp2 is discussed.
This article has been cited by other articles:
 |
|
 |
|
  W. Feng, R. E. Brown, C. D. Trung, W. Li, L. Wang, T. Khoury, S. Alrawi, J. Yao, K. Xia, and D. Tan Morphoproteomic Profile of mTOR, Ras/Raf Kinase/ERK, and NF-{kappa}B Pathways in Human Gastric Adenocarcinoma Ann. Clin. Lab. Sci., January 1, 2008; 38(3): 195 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Chiappetta, C. De Marco, A. Quintiero, D. Califano, S. Gherardi, D. Malanga, M. Scrima, C. Montero-Conde, L. Cito, M. Monaco, et al. Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer Endocr. Relat. Cancer, June 1, 2007; 14(2): 405 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Brown, D. Tan, J. S. Taylor, M. Miller, J. W. Prichard, and M. M. Kott Morphoproteomic Confirmation of Constitutively Activated mTOR, ERK, and NF-kappaB Pathways in High Risk Neuro-blastoma, with Cell Cycle and Protein Analyte Correlates Ann. Clin. Lab. Sci., January 1, 2007; 37(2): 141 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tzankov, A. Gschwendtner, F. Augustin, M. Fiegl, E. C. Obermann, S. Dirnhofer, and P. Went Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome. Clin. Cancer Res., April 1, 2006; 12(7): 2125 - 2132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mani and E. P. Gelmann The Ubiquitin-Proteasome Pathway and Its Role in Cancer J. Clin. Oncol., July 20, 2005; 23(21): 4776 - 4789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Knight, N. Sharma, and E. S. Robertson SCFSkp2 Complex Targeted by Epstein-Barr Virus Essential Nuclear Antigen Mol. Cell. Biol., March 1, 2005; 25(5): 1749 - 1763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kudo, S. Kitajima, I. Ogawa, M. Kitagawa, M. Miyauchi, and T. Takata Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation Mol. Cancer Ther., March 1, 2005; 4(3): 471 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kitajima, Y. Kudo, I. Ogawa, T. Bashir, M. Kitagawa, M. Miyauchi, M. Pagano, and T. Takata Role of Cks1 Overexpression in Oral Squamous Cell Carcinomas: Cooperation with Skp2 in Promoting p27 Degradation Am. J. Pathol., December 1, 2004; 165(6): 2147 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Osoegawa, I. Yoshino, S. Tanaka, K. Sugio, T. Kameyama, M. Yamaguchi, and Y. Maehara Regulation of p27 by S-Phase Kinase-Associated Protein 2 Is Associated With Aggressiveness in Non-Small-Cell Lung Cancer J. Clin. Oncol., October 15, 2004; 22(20): 4165 - 4173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yokoi, K. Yasui, M. Mori, T. Iizasa, T. Fujisawa, and J. Inazawa Amplification and Overexpression of SKP2 Are Associated with Metastasis of Non-Small-Cell Lung Cancers to Lymph Nodes Am. J. Pathol., July 1, 2004; 165(1): 175 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-I. Saez, A.-J. Saez, M.-J. Artiga, A. Perez-Rosado, F.-I. Camacho, A. Diez, J.-F. Garcia, M. Fraga, R. Bosch, S.-M. Rodriguez-Pinilla, et al. Building an Outcome Predictor Model for Diffuse Large B-Cell Lymphoma Am. J. Pathol., February 1, 2004; 164(2): 613 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Imaki, K. Nakayama, S. Delehouzee, H. Handa, M. Kitagawa, T. Kamura, and K. I. Nakayama Cell Cycle-dependent Regulation of the Skp2 Promoter by GA-binding Protein Cancer Res., August 1, 2003; 63(15): 4607 - 4613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Troncone, A Iaccarino, A Caleo, D Bifano, G Pettinato, and L Palombini p27Kip1 protein expression in Hashimoto's thyroiditis J. Clin. Pathol., August 1, 2003; 56(8): 587 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Quintanilla-Martinez, T. Davies-Hill, F. Fend, J. Calzada-Wack, L. Sorbara, E. Campo, E. S. Jaffe, and M. Raffeld Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis Blood, April 15, 2003; 101(8): 3181 - 3187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.-H. Shim, L. Johnson, H.-L. Noh, Y.-J. Kim, H. Sun, C. Zeiss, and H. Zhang Expression of the F-Box Protein SKP2 Induces Hyperplasia, Dysplasia, and Low-Grade Carcinoma in the Mouse Prostate Cancer Res., April 1, 2003; 63(7): 1583 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Z. Rassidakis, F.-X. Claret, R. Lai, Q. Zhang, A. H. Sarris, T. J. McDonnell, and L. J. Medeiros Expression of p27Kip1 and c-Jun Activation Binding Protein 1 Are Inversely Correlated in Systemic Anaplastic Large Cell Lymphoma Clin. Cancer Res., March 1, 2003; 9(3): 1121 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sanchez-Beato, A. Sanchez-Aguilera, and M. A. Piris Cell cycle deregulation in B-cell lymphomas Blood, February 15, 2003; 101(4): 1220 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Bergsagel Prognostic Factors in Multiple Myeloma: It's in the Genes Clin. Cancer Res., February 1, 2003; 9(2): 533 - 534. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sitry, M. A. Seeliger, T. K. Ko, D. Ganoth, S. E. Breward, L. S. Itzhaki, M. Pagano, and A. Hershko Three Different Binding Sites of Cks1 Are Required for p27-Ubiquitin Ligation J. Biol. Chem., October 25, 2002; 277(44): 42233 - 42240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Lim, A. Adamson, Z. Lin, B. Perez-Ordonez, R. C. K. Jordan, S. Tripp, S. L. Perkins, and K. S. J. Elenitoba-Johnson Expression of Skp2, a p27Kip1 ubiquitin ligase, in malignant lymphoma: correlation with p27Kip1 and proliferation index Blood, September 26, 2002; 100(8): 2950 - 2956. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
